Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis

Clinical Microbiology and Infection

Volumn 10, Issue 10, 2004, Pages 925-928

  Chandrasekar, P H ^a,b   Cutright, J L ^a   Manavathu, E K ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Amphotericin B; Aspergillosis; Guinea pig model; Micafungin; Pulmonary aspergillosis; Voriconazole

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; CYCLOPHOSPHAMIDE; KETAMINE; MICAFUNGIN; VORICONAZOLE; XYLAZINE;

ANESTHESIA INDUCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FUNGAL STRAIN; GUINEA PIG; LUNG ASPERGILLOSIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SURVIVAL RATE;

ANIMALIA; CAVIA; CAVIA PORCELLUS; SUS SCROFA;

EID: 6444222945     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2004.00958.x     Document Type: Article

References (17)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-803.
2. McNeil NM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States. Clin Infect Dis 2001; 33: 641-647.
3. Patterson TF, Kirkpatrick WR, White N et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. Medicine (Baltimore) 2002; 79: 250-260.
4. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
5. Maertens J, Raad I, Sable CA et al. Multicenter, non-comparative study to evaluate safety and efficacy of caspofungin (CAS) in adults with invasive aspergillosis (IA) refractory (R) or intolerant (I) to amphotericin B (AMB), AMB lipid formulations (Lipid AMB) or azoles [abstract M-868]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. Washington DC: American Society for Microbiology, 2002; 388.
6. Chandrasekar PH, Cutright JL, Alangaden GJ et al. In vitro susceptibility of Aspergillus fumigatus to conventional and lipid formulations of amphotericin B in 2-drug combination with caspofungin and micafungin. Int J Infect Dis 2002; 6 (suppl 2): 2.
7. Manavathu EK, Ganesan LT, Cutright JL et al. In vitro antifungal activity of voriconazole in two-drug combination with micafungin, caspofungin and amphotericin B [abstract J-125]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago. Washington DC: American Society for Microbiology, 2001; 364.
8. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy studies with caspofungin and amphotericin B against Aspergillus and Fusarium [abstract 932]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto. Washington DC: American Society for Microbiology, 2000; 368.
9. Kirkpatrick WR, Perea S, Coco BJ et al. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564-2568.
10. Chandrasekar PH, Cutright J, Manavathu EK. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model. J Antimicrob Chemother 2000; 45: 673-676.
11. Weisbroth SH, Fudens JH. Use of ketamine hydrochloride as an anesthetic in laboratory rabbits, rats, mice and guinea pigs. Lab Anim Sci 1972; 22: 904-906.
12. Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. J Infect Dis 1985; 15: 902-910.
13. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses 1993; 36: 421-424.
14. Kontoyiannis DP, Hachem R, Lewis RE et al. Efficacy and toxicity of the caspofungin/liposomal amphotericin B combination in documented or possible invasive aspergillosis in patients with hematologic malignancies [abstract M-1820]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego. Washington DC: American Society for Microbiology, 2002; 416.
15. Ratanatharathorn V, Flynn P, VanBurik J et al. Micafungin in combination with systemic antifungal agents in the treatment of refractory aspergillosis in bone marrow transplant patients [abstract 2472]. In: Abstracts of the 44th Annual Meeting of the American Society of Hematology. Philadelphia: American Society of Hematology, 2002; 627.
16. Aliff TB, Maslak PG, Jurcic JG et al. Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer 2003; 97: 1025-1032.
17. Petraitis V, Petraitiene R, Sarafandi AA et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834-1943.